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Abstract
Purpose The highest rates of gastric cancer occur in
Eastern Asia. Fluoropyrimidine-based therapy is used ini-
tially in unresectable and metastatic disease, but no single
standard of care exists following disease progression. Ixab-
epilone, an epothilone B analog, is a non-taxane microtu-
bule-stabilizing agent with clinical activity across multiple
tumor types approved by the United States Food and Drug
Administration for treatment of metastatic breast cancer.
Methods Asian patients with unresectable or metastatic
gastric adenocarcinoma who had failed fluoropyrimidine-
based chemotherapy received ixabepilone 40 mg/m2 by 3-h
intravenous infusion every 3 weeks. The primary endpoint
was objective response rate (ORR).
Results Fifty-two patients were treated (65.4 % men;
median age: 56.5 years). The ORR was 15.4 % (95 %
confidence interval [CI] 6.9–28.1); 8 patients achieved
partial responses for a median duration of 3.1 months
(95 % CI 2.6–4.1 months) and 26 patients (50.0 %) had
stable disease. Median progression-free survival was
2.8 months (95 % CI 2.1–3.5 months). The most common
grade 3 non-hematological toxicities were fatigue (9.6 %),
decreased appetite (7.7 %), sensory neuropathy (5.8 %),
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and diarrhea (5.8 %). Grade 3/4 neutropenia occurred in
46.2 % of patients.
Conclusions Ixabepilone is active in Asian patients with
advanced gastric cancer and shows a toxicity profile similar
to those previously reported in other tumor types.
Keywords Gastric cancer  Second-line therapy  Asian
patients  Ixabepilone
Introduction
Gastric cancer was newly diagnosed in an estimated
989,600 people and caused an estimated 738,000 deaths
worldwide in 2008 [1]; it was the third leading cause of
cancer deaths in men and fifth leading cause in women.
The highest rates of gastric cancer occur in Eastern Asia,
where the age-standardized incidence is 42.4 per 100,000
among men and 18.3 per 100,000 among women [1].
Surgery with curative intent is the mainstay of treatment in
localized disease, with perioperative chemotherapy or
adjuvant chemoradiation or chemotherapy for patients with
stage II or III disease depending on national standards
[2–4]. However, more than two-thirds of patients have
unresectable disease at the time of diagnosis and 60 % of
resectable cases eventually relapse [5, 6]. Non-curative
gastrectomy may be used in palliation, but it is associated
with high rates of procedure-related morbidity and mor-
tality as well as poor 1-year survival [7].
In the metastatic disease setting, combination chemo-
therapy with regimens containing a fluoropyrimidine and a
platinum agent is widely used initially, with a third cyto-
toxic agent often included for medically fit patients [2, 3].
Nevertheless, even with the most active regimens, pro-
gression-free survival (PFS) remains in the range of
5–7 months and median survival is only 9–11 months
[8–11]. In Japan, cisplatin plus the oral fluoropyrimidine
S–1 has emerged as a preferred first-line regimen producing
median survival of 13 months [12]. Following progression,
20–40 % of patients in Western countries subsequently
receive second-line chemotherapy [13], but the number is
higher (60–70 %) in Asian countries, particularly Japan and
Korea. There is no established second-line regimen; options
include paclitaxel, docetaxel, or irinotecan given alone or in
doublet regimens, which produced median survival of
4–8 months in prospective clinical trials [14–18]. These
survival data underscore the need for more effective therapy
in metastatic gastric cancer.
Ixabepilone is the first member of the epothilone class of
microtubule-stabilizing drugs to be approved for use in
cancer therapy, specifically monotherapy or in combination
with capecitabine for treatment of recurrent breast cancer
[19, 20]. Ixabepilone is structurally distinct from the
taxanes because it binds to a different site on b-tubulin and
has reduced susceptibility to common mechanisms that
confer resistance to taxanes and other anti-cancer drugs
[21, 22]. Phase II clinical studies have demonstrated that
ixabepilone has activity against a wide range of tumor
types besides breast cancer, including hormone-refractory
prostate cancer [23, 24], pancreatic cancer [25], non-small
cell lung cancer [26], endometrial carcinoma [27], ovarian
cancer [28], and renal cell carcinoma [29].
Ixabepilone administered every 3 weeks produced an
objective response rate (ORR) of 5 or 9 % in Western
patients with metastatic gastric cancer previously treated
with a fluoropyrimidine and/or a platinum [30] or a taxane
[31], respectively. Despite this modest activity in Western
patients, further evaluation of ixabepilone in Asian patients
with gastric cancer is warranted based on growing evi-
dence highlighting epidemiological and genetic differences
between Asian and Western populations [32]; gene expres-
sion profiling revealed differential expression of multiple
genes in Eastern versus Western gastric tumor libraries [33].
Moreover, several retrospective analyses have shown that
Asian patients are more likely to be diagnosed with localized
tumors and have tumors located in the gastric antrum,
whereas Western patients are more likely to have distant
metastases and a prognostically less favorable tumor loca-
tion in the cardia [34–36]. In these retrospective cohorts,
median survival was longer in Asian patients than in Western
patients, likely reflecting the differences in disease charac-
teristics at presentation.
The present phase II study was designed to evaluate the
efficacy and safety of single-agent ixabepilone in Asian
patients with advanced gastric adenocarcinomas in which
prior fluoropyrimidine-based therapy had failed. The primary
objective was to determine the ORR; secondary objectives
were to assess time to response, duration of response, disease
control rate (DCR), PFS, and safety and tolerability.
Methods
Patients
Men and women of Asian ethnicity aged C18 years with
histologically confirmed unresectable or metastatic gastric
adenocarcinoma originating in the stomach or gastro-
esophageal junction were eligible if a fluoropyrimidine-
based chemotherapy regimen had failed in an adjuvant,
locally advanced, or metastatic setting. Failure of fluoro-
pyrimidine-based chemotherapy was defined by disease
progression while receiving such therapy or by disease
recurrence within 12 months of the last dose. Eligibility
also required measurable disease by response evaluation
criteria in solid tumors (RECIST) guidelines (version 1.1)
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[37], Eastern Cooperative Oncology Group performance
status 0–1, adequate hematologic, hepatic, and renal
function, and life expectancy [12 weeks. Women of
childbearing potential required a negative pregnancy test
within 72 h before starting ixabepilone and agreed to use
an adequate method of contraception to avoid pregnancy
for up to 4 weeks after the last dose. All patients provided
written informed consent before participating in this study.
Patients were excluded if they had known central ner-
vous system metastasis or neurological signs and symptoms
suggestive of such metastasis, prior taxane or ixabepilone
therapy, peripheral neuropathy (Cgrade 2), or any signifi-
cant medical illness precluding systemic anticancer therapy.
Patients who had received[1 prior chemotherapy regimen
for metastatic disease or [2 prior chemotherapy regimens
overall were ineligible. Concurrent anti-cancer treatment
including investigational agents was not permitted during
this study. Strong CYP3A4 inhibitors (e.g., ketoconazole)
were discontinued within 1 week prior to starting study
treatment.
Study design
This phase II, single-arm, open-label study was conducted at
9 sites in Asia including 2 sites in Japan, 3 sites in Korea, 2
sites in Taiwan, and 1 site each in Hong Kong and Singapore
from November of 2009 to June of 2011. The study was run
in accordance with ethical principles originating in the 1964
Declaration of Helsinki and in compliance with Good Clin-
ical Practice and national regulatory guidelines. The study
protocol and informed consent form were approved by the
Institutional Review Board or Independent Ethics Commit-
tee at each study site before patient enrollment.
Ixabepilone was administered at a dose of 40 mg/m2 as a
3-h infusion every 21 days. Premedication with H1 and H2
antagonists was given to prevent hypersensitivity reactions.
Patients who experienced a hypersensitivity reaction were
required to receive additional premedication with intrave-
nous corticosteroids before subsequent ixabepilone doses.
Subsequent cycles of ixabepilone were administered
after all treatment-related toxicities had resolved to base-
line or grade 1 (or Bgrade 2 for alopecia and fatigue),
absolute neutrophil counts were C1,500 cells/lL, and
platelet counts were C100,000 cells/lL. Patients who did
not meet these criteria were re-evaluated weekly; those
who failed to recover within 3 weeks of a scheduled
re-treatment were discontinued from protocol treatment.
The duration of treatment was based on a tumor assessment
done every other cycle starting from the first dose of the
study treatment. Patients achieving a complete response
(CR) were treated for a maximum of 4 cycles after docu-
mentation of CR or up to a maximum of 8 cycles,
whichever came first. Patients with stable disease (SD) or a
partial response (PR) were treated until disease progres-
sion, unacceptable toxicity, or a maximum of 8 cycles.
Patients experiencing certain toxicities had the dose of
ixabepilone reduced in subsequent cycles to 32 mg/m2,
and if toxicity recurred, to 25 mg/m2. Toxicities mandating
dose reduction were grade 4 neutropenia lasting C7 days,
febrile neutropenia, grade 4 thrombocytopenia, grade 3
thrombocytopenia with bleeding, grade 2 neuropathy lasting
C7 days, or grade 3 neuropathy lasting \7 days. The
reduced dose was then administered in all subsequent cycles.
Ixabepilone was discontinued for toxicity requiring more
than 2 dose reductions or in the event of grade 3 neuropathy
lasting C7 days, disabling neuropathy, or any grade 4 non-
hematologic toxicity. Palliative and supportive care for
disease-related symptoms was allowed during the study.
Assessments
Clinical and radiological evaluation (abdominal and chest
computed tomography) of treatment response was conducted
every other cycle until disease progression was documented.
Treatment response was evaluated according to modified
RECIST guidelines (version 1.1) [37]. Patients with CRs
or PRs were to have repeat tumor assessments within
4–6 weeks to confirm the response. The ORR was the pro-
portion of patients who achieved either a CR or PR; the DCR
was the proportion of patients whose best response was CR,
PR, or SD. The time to response was defined as the time
interval from the first dose of ixabepilone until measurement
criteria for PR or CR were first met, whereas the duration of
response was defined as the time interval from when mea-
surement criteria for PR or CR were first met until docu-
mented progressive disease or death. PFS was defined as the
time interval from the first day of treatment until documented
progressive disease or death.
A focused physical examination, including neuropathy
assessment, was performed within 2 weeks before the first
dose of ixabepilone and then prior to each subsequent dose.
Serum chemistry and hematology were measured at the
same time, whereas blood counts and differentials were
ordered weekly during the first 3 cycles and then as clini-
cally indicated to monitor recovery from hematological
toxicity. Adverse events were monitored continuously and
graded according to the National Cancer Institute Common
Terminology Criteria of Adverse Events, version 3.0.
Statistics
This study used Simon’s 2-stage optimal design to determine
whether ixabepilone produces an ORR of clinical interest
([8 %); an ORR B8 % was not of clinical interest and an
ORR C20 % was of strong clinical interest. The first stage
required 25 response-evaluable patients. Study termination
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was planned if B2 of the 25 patients responded to treatment;
otherwise, an additional 27 response-evaluable patients
would be treated. The study required at least 8 responders
among the 52 evaluable patients at the end of the second
stage to reject the null hypothesis of ORR B8 %. The test had
80 % power to reject the null hypothesis at a significance
level of 5 % if the true ORR is 20 %.
The ORR and DCR were calculated for all treated
patients. For each, a 2-sided 95 % exact confidence interval
(CI) was computed using the Clopper–Pearson method.
Duration of response and PFS were analyzed by Kaplan–
Meier methodology, with computation of median values and
their 2-sided 95 % CIs. All other parameters, including time
to response, demographic and baseline characteristics, and
safety variables, were analyzed with descriptive statistics.
Results
Patient disposition and characteristics
Fifty-eight patients were screened, 6 (10.3 %) were not
treated because of screening failure, and the remaining 52
patients (89.7 %) were enrolled and received ixabepilone.
Of those treated, 4 patients (7.7 %) completed ixabepilone
therapy according to the study protocol, 38 patients
(73.1 %) discontinued because of disease progression, 5
patients (9.6 %) withdrew consent or requested study drug
discontinuation, 4 patients (7.7 %) discontinued because of
adverse events, and 1 patient (1.9 %) died.
The median age of the study cohort was 56.5 years
(range: 29.0–77.0 years); most were men (65.4 %) and all
were of Asian ethnicity (Table 1). The majority of patients
had 3 or more disease sites (53.8 %), most frequently in
the lymph nodes (71.2 %), stomach (55.8 %), and liver
(36.5 %).
Exposure
Ixabepilone was administered for a median of 3.5 courses
(range: 1–10). Of the 45 patients who received at least 2
courses, 18 (40 %) required at least 1 dose reduction of
ixabepilone. The reasons for the first dose reduction
included hematologic toxicity in 6 patients (13.3 %), neu-
ropathy in 4 patients (8.9 %), and other non-hematologic
toxicity in 8 patients (17.8 %).
Efficacy
The ORR with ixabepilone therapy was 15.4 % (95 % CI
6.9–28.1); all objective responses were PR (Table 2).
Twenty-six additional patients (50.0 %) had SD and,
therefore, the DCR was 65.4 % (95 % CI 50.9–78.0). For
patients achieving PR, the median time to response was
8.9 weeks (range: 5.1–12.1 weeks) and the median duration
of response was 3.1 months (95 % CI 2.6–4.1 months).
Median PFS was 2.8 months (95 % CI 2.1–3.5 months)
(Fig. 1).
Safety
The adverse events reported were consistent with the
known safety profile of ixabepilone. Fifty patients (96.2 %)
had at least 1 adverse event, most commonly alopecia,
Table 1 Patient characteristics
Characteristic N = 52
Age, years
Median (range) 56.5 (29.0–77.0)
C65 years, n (%) 12 (23.1)
Gender, n (%)
Male 34 (65.4)
Female 18 (34.6)
Ethnicity, n (%)
Chinese 23 (44.2)
Japanese 15 (28.9)
Korean 13 (25.0)
Asian other 1 (1.9)
ECOG performance status, n (%)
0 20 (38.5)
1 32 (61.5)
Number of disease sites, n (%)
1 11 (21.2)
2 13 (25.0)
C3 28 (53.8)
Disease sites, n (%)
Lymph node 37 (71.2)
Gastric 29 (55.8)
Peritoneum (including ascites) 23 (44.2)
Liver 19 (36.5)
Lung 8 (15.4)
Other 30 (57.7)
ECOG Eastern Cooperative Oncology Group
Table 2 Best overall response
Parameter N = 52
Best response, n (%)
CR 0 (0)
PR 8 (15.4)
SD 26 (50.0)
Progressive disease 15 (28.8)
Unable to determine 3 (5.8)
ORR (95 % CI) 15.4 (6.9–28.1)
DCR (95 % CI) 65.4 (50.9–78.0)
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decreased appetite, neutropenia, peripheral sensory neu-
ropathy, and fatigue (Table 3). Most non-hematologic
toxicity was grade 1 or 2; the most common grade 3 events
were fatigue (9.6 %), decreased appetite (7.7 %), periph-
eral sensory neuropathy (5.8 %), and diarrhea (5.8 %).
Overall, peripheral neuropathies were reported by 33
patients (63.5 %), with the most common forms being
peripheral sensory neuropathy (48.1 %) and hypoesthesia
(11.5 %). Peripheral motor neuropathy occurred in 1
patient (1.9 %; grade 2). In terms of hematological toxic-
ity, grade 3/4 neutropenia and leukopenia occurred in 24
(46.2 %) and 11 (21.1 %) patients, respectively, with feb-
rile neutropenia in 4 patients (7.7 %). Grade 3 anemia and
thrombocytopenia occurred in 3 (5.8 %) and 2 (3.8 %)
patients, respectively.
Four patients (7.7 %) discontinued treatment because of
drug-related adverse events, including 3 patients with
peripheral neuropathy and 1 patient with febrile neutrope-
nia. There was 1 death because of drug-related toxicity: a
69-year-old male patient died of pneumonia and neutro-
penic sepsis during course 6 of ixabepilone therapy. The
patient started course 6 with a reduced dose of 32 mg/m2
because the investigator had considered the patient too
weak to continue at the initial dose. The death occurred
18 days after the last treatment. Three other patients died
within 30 days of their last dose of ixabepilone, all of
which were assessed by the investigator as due to disease
progression.
Discussion
The results of this phase II study demonstrate that ixab-
epilone has activity of clinical interest when administeredFig. 1 Kaplan–Meier plot of progression-free survival
Table 3 Treatment-related
adverse events (AEs) reported
at an incidence C10 %
a Includes 1 patient with grade
5 pneumonia and neutropenic
sepsis
AE Grade 1 Grade 2 Grade 3 Grade 4 Total
Any AE 7 (13.5) 11 (21.2) 12 (23.1) 19 (36.5) 50 (96.2)a
Hematologic AEs
Neutropenia 0 (0) 2 (3.8) 8 (15.4) 16 (30.8) 26 (50.0)
Leukopenia 0 (0) 1 (1.9) 9 (17.3) 2 (3.8) 12 (23.1)
Non-hematologic AEs
Alopecia 26 (50.0) 9 (17.3) 0 (0) 0 (0) 35 (67.3)
Decreased appetite 14 (26.9) 11 (21.2) 4 (7.7) 0 (0) 29 (55.8)
Peripheral sensory neuropathy 12 (23.1) 10 (19.2) 3 (5.8) 0 (0) 25 (48.1)
Fatigue 5 (9.6) 12 (23.1) 5 (9.6) 0 (0) 22 (42.3)
Rash 11 (21.2) 5 (9.6) 1 (1.9) 0 (0) 17 (32.7)
Diarrhea 10 (19.2) 1 (1.9) 3 (5.8) 0 (0) 14 (26.9)
Constipation 9 (17.3) 4 (7.7) 0 (0) 0 (0) 13 (25.0)
Nausea 8 (15.4) 4 (7.7) 1 (1.9) 0 (0) 13 (25.0)
Myalgia 9 (17.3) 2 (3.8) 1 (1.9) 0 (0) 12 (23.1)
Arthralgia 7 (13.5) 4 (7.7) 0 (0) 0 (0) 11 (21.2)
Weight decreased 2 (3.8) 9 (17.3) 0 (0) 0 (0) 11 (21.2)
Pruritus 6 (11.5) 3 (5.8) 0 (0) 0 (0) 9 (17.3)
Pyrexia 8 (15.4) 0 (0) 0 (0) 0 (0) 8 (15.4)
Vomiting 5 (9.6) 3 (5.8) 0 (0) 0 (0) 8 (15.4)
Stomatitis 2 (3.8) 3 (5.8) 2 (3.8) 0 (0) 7 (13.5)
Asthenia 1 (1.9) 5 (9.6) 0 (0) 0 (0) 6 (11.5)
Dysgeusia 5 (9.6) 1 (1.9) 0 (0) 0 (0) 6 (11.5)
Hypoesthesia 2 (3.8) 3 (5.8) 1 (1.9) 0 (0) 6 (11.5)
Nail disorder 5 (9.6) 0 (0) 1 (1.9) 0 (0) 6 (11.5)
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at a dose of 40 mg/m2 every 21 days to Asian patients with
unresectable or metastatic gastric cancer who had pro-
gressed on or within 12 months after receiving fluoropyr-
imidine-based therapy. In this population, ixabepilone
produced an ORR of 15.4 % and DCR of 65.4 %. This is in
contrast to the lower ORRs of 5 % and 9 % reported for
50 mg/m2 ixabepilone administered every 21 days in
Western patients with metastatic gastric cancer previously
treated with a fluoropyrimidine and/or a platinum [30] or a
taxane [31], respectively.
The activity of ixabepilone appears consistent with
contemporary studies of taxanes in second-line treatment
of Asian patients with advanced gastric cancer. Docetaxel
produced ORRs of 14–16 % in phase II trials conducted in
Korea [15, 38]. In the largest of these studies, docetaxel
was administered to 154 patients who had failed fluoropyr-
imidine and platinum therapy, of whom 86 were evaluable
for response; the ORR and DCR were 14 and 43 %,
respectively, and median time to progression was
2.6 months [38]. Rates up to 24 % were reported for doce-
taxel in Japanese patients with recurrent or metastatic gastric
cancer, but these studies were conducted more than a decade
ago and, consequently, patients may not have received
optimal initial chemotherapy [39, 40]. In a recent Japanese
study, biweekly paclitaxel after failure of fluoropyrimidine-
based therapy produced an ORR of 17.5 % and DCR of
70.0 % with a median PFS of 3.6 months [16]. Besides
taxanes, other cytotoxic agents including irinotecan have
shown similar activity in advanced gastric cancer [41],
whereas various targeted agents have shown modest single-
agent activity in this setting [42].
Although multiple drugs have been evaluated as second-
line therapy in phase II trials and retrospective cohorts,
there have been no randomized head-to-head trials
designed to establish a standard treatment in this setting
[43]. Comparisons of second-line therapy across clinical
studies are problematic for multiple reasons, including the
nature of previous chemotherapy and responses to first-line
chemotherapy [13]. This is particularly important in
advanced gastric cancer since response duration to first-line
chemotherapy is prognostic for the benefit of second-line
chemotherapy [44, 45]. With targeted agents being
increasingly tested in conjunction with first-line chemo-
therapy, it will be important to evaluate how they impact
the activity of subsequent second-line treatment and, con-
versely, how second-line therapy affects outcomes mea-
sured with first-line regimens [43].
Current treatment options in second-line advanced gastric
cancer provide only small overall survival (OS) benefit over
best supportive care (BSC). A recent randomized phase III
trial of 193 Asian patients assessed the efficacy and safety of
BSC combined with either docetaxel (60 mg/m2 every
3 weeks) or irinotecan (150 mg/m2 every 2 weeks) com-
pared with BSC alone as a second-line therapy in advanced
gastric cancer [17]. The OS of patients randomized to BSC
plus docetaxel or irinotecan (n = 128) versus BSC alone
(n = 65) was 5.1 and 3.8 months, respectively; the differ-
ence was statistically significant (hazard ratio, 0.63; 95 % CI
0.47–0.86; P = 0.004) and was maintained in most of the
prospectively defined subgroups including age, gender,
performance status, number of prior treatments, number of
metastatic sites, hemoglobin levels, and response to prior
chemotherapy. Docetaxel or irinotecan improves OS when
added to BSC in second-line advanced gastric cancer, but the
OS improvement of 1.3 months over BSC only underscores
the current unmet medical need for more efficient treatments
in this patient population. Another recent phase III trial
comparing single-agent irinotecan versus BSC in Germany
was closed prematurely after accrual of only 40 patients [18].
Irinotecan produced no objective responses and SD in 53 %,
but showed a statistically significant improvement in median
OS (4.0 vs 2.4 months; P = 0.012).
In Asian gastric cancer patients, ixabepilone showed a
safety profile similar to that previously reported in other
tumor types. Grade 3/4 toxicity consisted mostly of neu-
tropenia, whereas the most clinically relevant treatment-
related non-hematological adverse events were decreased
appetite (anorexia), peripheral sensory neuropathy, and
fatigue, mostly grade 1 or 2 in severity. In an earlier study
conducted in Western patients with gastric cancer, nausea,
fatigue, sensory neuropathy, vomiting, and anorexia were
commonly seen with ixabepilone given every 3 weeks at a
higher dosage (50 mg/m2) than the one used in this study;
frequencies of each of these events except for fatigue
reduced when a lower ixabepilone dose was administered
over a 5-day period every 3 weeks [31]. At the dose used in
this study (40 mg/m2 every 3 weeks, the approved regimen
in breast cancer), the incidence of peripheral sensory
neuropathy and fatigue was consistent with rates seen in
clinical trials of other tumor types and in other studies of
recurrent disease, including breast cancer [19, 20] and
endometrial carcinoma [27]. Gastrointestinal adverse
events were also common across tumor types, although the
nature of these events (e.g., anorexia, nausea) varied in
incidence. In general, the safety profile of ixabepilone is
better in earlier lines of therapy as demonstrated in the
TITAN study of patients with metastatic breast cancer
treated in a first-line setting [46].
In summary, ixabepilone showed clinical activity with
an ORR of 15.4 % in Asian patients with unresectable or
metastatic gastric cancer in whom fluoropyrimidine-based
chemotherapy had failed. Ixabepilone therapy was tolera-
ble for most patients and its safety profile was similar to
that previously reported in other tumor types.
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